 |
市場調查報告書
甲狀腺疾病的全球市場:2020-2027年Global Thyroid Gland Disorders Therapeutics Market - 2020-2027 |
||||||
| 出版商 | DataM Intelligence | 商品編碼 | 965966 | ||||
| 出版日期 | 按訂單生產 | 內容資訊 | 英文 商品交期: 請詢問到貨日 |
||||
| 價格 |
|
||||||
| 甲狀腺疾病的全球市場:2020-2027年 Global Thyroid Gland Disorders Therapeutics Market - 2020-2027 | ||
| 出版日期: 按訂單生產 | 內容資訊: 英文 |
|
全球甲狀腺疾病治療藥市場成長，主要由於碘缺乏症人口增加的負擔而受到推動。碘缺乏症，原因主要是飲食中碘的攝取數量少。碘缺乏症，不僅在歐洲各國，在亞太地區及非洲的低中所得國也普遍增加。根據National Institutes of Health (NIH) ，碘缺乏症的盛行率，在更許多罹患甲狀腺疾病病的美國和墨西哥的山岳地帶變高。
本報告提供全球甲狀腺疾病治療市場相關調查，市場概要，各市場區隔及各地區的市場規模的預測，主要企業的簡介，競爭情形分析等系統性資訊。
The global thyroid gland disorders therapeutics market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).
Thyroid gland-related disorders are caused due to the inefficiency of the thyroid gland to produce enough thyroid hormones. Thyroid disorders are mainly caused due to a deficiency of iodine in the body. Thyroid disease is most common in adults aged 30-50 years, but all age groups are affected. Cretinism and neonatal myxedema manifest in the intrauterine/perinatal period. Thyroid medications encompass an array of different options, which differ not only in their composition but their intent. Hormone replacement therapy, such as Synthroid (levothyroxine), is the most widely used drug for hypothyroidism. An anti-thyroid drug such as Tapazole (methimazole) are used for hyperthyroidism, and thyroid cancer patients may require or radioactive-iodine therapy or chemotherapy.
Rising burden of the population with iodine deficiency is driving the market growth
The global thyroid gland disorders therapeutics market growth is primarily driven by the rising burden of the population with iodine deficiency. Iodine deficiency is majorly caused by low intake of iodine in the diet. According to the World Health Organization (WHO), it is recommended that the daily intake (RDI) of iodine should be around 150 mcg per day, which is sufficient for more than 95% of all healthy adults, with pregnant and lactating women needing more. Iodine deficiency is growing commonly in the European countries, as well as in the low- and middle-income countries in Asia-Pacific and Africa. As per the National Institute of Health, the prevalence of iodine deficiency is higher in the mountainous regions of the United States and Mexico, where more number of people are falling prey to thyroid diseases.
Epidemiology
In the United States, thyroid disease is common in adults. According to a survey, the prevalence of hypothyroidism to be 1.4% in adult females and 0.1% in adult males. The prevalence of Graves disease, a hyperthyroid condition, is 1.9% in females and about 0.19% in males. Peak age incidence is in the range of 30-50 years. The congenital disease occurs in 1 per 4000 neonates in North America and Western Europe. This is seen more frequently in areas of iodine deficiency.
Globally, about 1 billion people are at risk for iodine deficiency disorders. Endemic goiter is most common manifestation and has a varying prevalence. In communities with severe iodine deficiency, prevalence is 5-15% but can reach 100%. This situation occurs in developing countries.
COVID-19 Impact Analysis
The COVID-19 is affecting the global economy by directly affecting production and demand, by disturbing the supply chain and market disruption, and by its financial impact on firms and financial markets. The global thyroid gland disorders therapeutics market has slowed down from the COVID-19 pandemic, as stakeholders are increasingly searching for newer approaches towards diagnosing and curing patients affected by the COVID-19.
The global thyroid gland disorders therapeutics market is segmented on the basis of disease type, drug class, route of administration, and distribution channel.
By Disease type, Hyperthyroidism is expected to witness rapid growth
Hyperthyroidism is a disorder in which the thyroid gland produces thyroxin in the large amount. According to the National Institute of Health, the prevalence of the hyperthyroidism is expected to be around 1-1.3%, and it increases up to 4-5% in older women.
Also, the disease is more commonly occurs in smokers. As smoking is rising among the general population globally, an increasing number of people are falling prey to the disease. In addition, the awareness towards the hyperthyroidism is growing in developing countries, such as India, which is expected to drive the growth of the market.
The treatment of hyperthyroidism is generally more complex than hypothyroidism, requiring one or more treatments such as Anti-thyroid drug, Radioactive iodine (RAI), Surgery to remove the gland (thyroidectomy). The only medications for hyperthyroidism are anti-thyroid drugs. Tapazole (methimazole, or MMI) and Propylthiouracil (PTU) are currently two approved for use in treating hyperthyroidism in the United States.
In December 2019, Life science company Bioiberica has launched a natural thyroid active pharmaceutical ingredient (API) for the treatment of hypothyroidism.
Thyroid hormones segment is expected to account for the largest market share during the forecast period
Levothyroxine (Synthroid, Levoxyl): Levothyroxine is synthetic, but it is identical to natural T4; in its active form, levothyroxine influences the growth and maturation of tissues; it is involved in normal growth, metabolism, and development.
Liothyronine (Cytomel, Triostat): Liothyronine is a synthetic form of T3 (triiodothyronine). Brand names of liothyronine in the United States are Cytomel and Triostat. Due to the fact that experts, for the most part, recommend T4-monotherapy and not combination T4/T3 therapy for treating hypothyroidism, this medication is not commonly prescribed.
Propylthiouracil (PTU): Propylthiouracil is a derivative of thiourea that inhibits organification of iodine by the thyroid gland. It also inhibits the conversion of T4 to T3, which is advantage over other agents.
Methimazole (Tapazole): Methimazole suppresses thyroid function and has a mechanism similar to that of PTU; it does not inhibit peripheral conversion of T4 to T3. Methimazole is fifteen times as potent as PTU. PTU-equivalent dosing can be used, divided thrice daily.
Propranolol (Inderal): This nonselective, beta-adrenergic blocking agent treats symptomatic tachycardia. Propranolol has membrane-stabilizing activity and decreases the automaticity of contractions.
Potassium chloride (K-DUR): Potassium chloride is essential for the transmission of nerve impulses, maintenance of intracellular tonicity, and maintenance of normal renal function. It is also vital for skeletal and smooth muscles. Potassium chloride replaces potassium lost in thyrotoxic periodic paralysis.
Corticosteroids: These agents provide immunosuppressive therapy for Graves ophthalmopathy, especially in cases of severe exophthalmos.
Prednisone (Deltasone, Sterapred, Orasone): Prednisone is a widely used glucocorticoid that suppresses inflammatory processes by reversing increased capillary permeability and suppressing PMN activity; it is used to treat allergic, inflammatory, and autoimmune disorders.
Tricyclic antidepressants: These agents may help relieve painful polyneuropathy.
Amitriptyline (Elavil): By inhibiting the reuptake of serotonin and/or norepinephrine by presynaptic neuronal membrane, amitriptyline may increase the synaptic concentration of these neurotransmitters in the CNS; it is useful as an analgesic for certain chronic and neuropathic pain.
Gabapentin (Neurontin): Gabapentin's exact mechanism is unknown. It is structurally related to GABA and is useful in some pain syndromes
Geographical Analysis
North America region holds the largest market share in global Thyroid Gland Disorders Therapeutics market
North America region is dominating the global thyroid gland disorders therapeutics market accounted for the largest market share in 2019, owing to the high prevalence rate for thyroid disorders in the United States, rising risk factors such as obesity and diabetes, and well-established healthcare infrastructure.
In North America, around 35 million people suffer from at least one form of thyroid disease. As per the American Association of Clinical Endocrinologists (AACE) survey, around 13 million people or 4.80% of the population, had thyroid disorders in the United States in 2016. Also, as per the American Thyroid Association, in 2017, around 4.6% of the US population had hypothyroidism, and 1.3% had hyperthyroidism.
Various companies have collaborated with the America Thyroid Association (ATA), as the association has supported various research grants worth about US$ 2.2 million. Several large players are involved in raising awareness in American society through campaigns towards thyroid disorders. For instance, in 2017 and 2018, Merck launched "It is not you. It is your thyroid" campaign. The awareness campaign is in collaboration with the Thyroid Federation International (TFI), as it is observed by companies that the thyroid disorders are underdiagnosed.
In January 2020, The American Association of Clinical Endocrinologists launched the Up To Here campaign to raise awareness of thyroid diseases and to help U.S. residents recognize symptoms, risk factors and the need to seek treatment. The campaign, launched to coincide with Thyroid Awareness Month, is designed to highlight common symptoms associated with thyroid disease, such as weight gain and mood or sleep disorders.
Asia-Pacific region is growing at the fastest CAGR during the forecast period.
The Asia Pacific market is expected to grow at the fastest CAGR during the forecast period, due to the rising demand for thyroid treatments in developing countries such as China, India, and South Korea. These countries are emerging as major destinations for outsourcing clinical trials, drug manufacturing, and pathology testing. The development of effective drug therapies for thyroid disorders and rise in the number of disease awareness programs in developing countries are responsible for the market growth in this region.
The thyroid gland disorders therapeutics market is moderately competitive and majorly consists of the global players. The rising drug development may witness the entry of few small- or mid-sized companies in the market during the forecast period. Some of the key players which are contributing to the growth of the market include Abbvie Inc., GlaxoSmithKline PLC, Amgen Inc., Novartis AG, Mylan NV, Merck KGaA, Pfizer Inc., Takeda Pharmaceutical Company Limited, among others.
Pfizer Inc.
Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology. Its products include the blockbuster drug Lipitor (atorvastatin), used to lower LDL blood cholesterol; Lyrica (pregabalin) for neuropathic pain and fibromyalgia; Diflucan (fluconazole), an oral antifungal medication; Zithromax (azithromycin), an antibiotic; Viagra (sildenafil) for erectile dysfunction; and Celebrex (also Celebra, celecoxib), an anti-inflammatory drug.
Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer
Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
Pituitary Thyroid-Stimulating Hormone (TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer .
Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy
The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the thyroid gland disorders therapeutics gobally. For instance,
The global thyroid gland disorders therapeutics market report would provide an access to an approx. 69 market data table, 66 figures and 300 pages.
LIST NOT EXHAUSTIVE
全球甲狀腺疾病治療市場(2020年∼2024年)
甲狀腺疾病治療藥的全球市場 (疾病的各類型、治療藥的各類型、各地區):產業展望，綜合分析，未來預測 (2019年∼2026年)
全球甲狀腺疾病治療藥市場:各疾病類型、給藥途徑、醫藥品分類、通路、地區(2018年∼2023年)
全球甲狀腺疾病治療市場調查與預測
甲狀腺疾病治療市場:各疾病類型，藥物類別，給藥途徑，各流通/銷售管道:全球機會分析與產業預測
全球甲狀腺疾病治療市場分析:各適應症(甲狀腺機能低下症，甲狀腺功能亢進症)，各給藥途徑(口服，靜脈內)，各流通管道，市場區隔預測(2018∼2025年)
甲狀腺疾病治療的全球市場 (甲狀腺機能低下症及甲狀腺功能亢進症) - 產業分析、規模、構成比、成長率、趨勢及預測：2015-2023年
